Pharmaceutical Technology on MSN10d
Augustine secures $85m to advance Charcot-Marie-Tooth candidateAGT-100216 will now enter a Phase I/II proof-of-concept clinical trial for CMT disease, with patient enrolment set to begin ...
Augustine Therapeutics has raised €78 million ($85 million) in first-round funding for a pipeline headed by a candidate for ...
Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing round Novo Holdings and Jeito Capital co-led the ...
The German firm licensed a PRMT5 inhibitor that’s now in Phase 1 testing. Elsewhere, GSK is testing an intriguing hypothesis ...
By Karen Roman Private equity company Jeito Capital said it is co-leading an oversubscribed €77.7 million (USD 84.8 million) ...
Novo Holdings and Jeito Capital co-led the deal, supported by Asabys Partners and existing investors Proceeds to support the clinical development of lead candidate AGT-100216 for the treatment of ...
Proceeds to support the clinical development of lead candidate AGT-100216 for the treatment of Charcot-Marie-Tooth (CMT) disease, with Phase I trials starting imminently Pipeline of next ...
Novo Holdings and Jeito Capital co-led the deal, supported by Asabys Partners and existing investors Proceeds to support the clinical development of lead candidate AGT-100216 for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback